Novo Nordisk's Balancing Act: Buybacks, AI Bets, and a Legal Shield While the Stock Stalls

Despite $1.2B buyback and raised guidance, Novo Nordisk stock slides 28% from highs as CEO defends obesity strategy amid Lilly rivalry.

Novo Nordisk is running a two-front campaign — returning billions to shareholders while pouring resources into artificial intelligence and courtroom defenses — yet the Danish pharma giant's shares remain stuck in a rut that no amount of corporate activity seems able to lift.

The company disclosed on August 17 that it had repurchased 28,884,179 B-shares at an average price of 279.80 Danish kroner through August 14, bringing the total transaction value to 8.08 billion kroner. That figure represents a meaningful chunk of the broader 15 billion kroner buyback program, which runs for twelve months from February 4, 2026.

A Stock That Won't Cooperate

The buyback's inability to prop up the share price tells its own story. The stock last traded at 38.83 euros in the secondary article, having shed 11 percent over the preceding 30 days — a steeper slide than the 9.1 percent monthly decline cited in the primary source, where the share price stood at 39.52 euros. Both versions agree on the broader picture: the equity sits roughly 28 to 29 percent below its 52-week high of 54.86 euros, reached in January, and has lost about 10 percent on a year-to-date basis.

Technical indicators paint a similarly cautious picture. The relative strength index sits at 38.5, putting the stock in oversold territory, yet it continues to trade below both its 50-day moving average of 41.44 euros and its 200-day average of 40.26 euros. The stock has recovered 31 percent from its March low of 30.25 euros, but the recent momentum — including a 14.1 percent decline since the buyback was last reported roughly three weeks ago — suggests investors are waiting for more tangible evidence of a turnaround.

Doustdar's Defense

CEO Mike Doustdar pushed back on investor skepticism in a Reuters interview last Thursday, arguing that the market underestimates demand for differentiated obesity treatments. His central thesis: oral options and a broader portfolio will prevent the weight-loss market from collapsing into a winner-take-all duel with Eli Lilly.

That conviction extends to CagriSema, the combination therapy Novo Nordisk plans to launch next year despite clinical data showing weight-loss results trailing Lilly's Zepbound. Doustdar's strategy is diversification rather than a single flagship product — a philosophy he reinforced earlier this month in the Wall Street Journal, where he left the door open for smaller acquisitions while ruling out transformative deals.

The half-year results, published roughly two weeks ago, lent some credibility to that approach. Adjusted operating profit came in at 33,389 million Danish kroner, and management raised its full-year guidance for both adjusted revenue growth and operating profit. The market's initial response was a 1.1 percent uptick, but disappointing study data roughly two weeks later knocked the stock down 2.7 percent.

AI and the Legal Front

While the market digests those mixed signals, Novo Nordisk is quietly building out its technological capabilities. The company and Amazon Web Services recently expanded their strategic partnership, establishing a joint innovation center in London where engineers and scientists are applying AWS's AI tools to Novo Nordisk's data. The stated goal: compress the timeline from drug target identification to first human application. Management claims measurable progress already, including reduced documentation times in clinical trials, and says more than 25,000 employees stand to benefit from the productivity gains.

On the legal side, the company has notched two victories this month. A US federal judge dismissed an antitrust lawsuit filed by a compounding manufacturer that accused Novo Nordisk and Eli Lilly of blocking access to customized GLP-1 medications. Days later, a Dutch district court issued a preliminary injunction against Ceban Ziekenhuisfarmacie B.V. over a semaglutide nasal spray that infringed a Novo Nordisk patent. The court ordered Ceban to halt its activities, remove product listings, disclose supply chain information, and cover Novo Nordisk's legal costs.

The Dutch ruling underscores how aggressively the company defends its intellectual property around its blockbuster GLP-1 franchise — a priority that grows more pressing as copycat products proliferate.

What Investors Are Watching

With the stock trading below key technical levels and sentiment still fragile, the next major catalyst arrives on November 4, when Novo Nordisk reports third-quarter results. Until then, the interplay between the buyback program, the AWS collaboration, and the company's legal victories will likely determine whether the shares can finally find their footing — or whether Doustdar's confidence in the obesity market's breadth proves more aspirational than the current price action suggests.